Phase 3 — Semaglutide 2.4 mg (Wegovy)
STEP 5: trial summary, limitations and UK relevance
Body-weight reduction with semaglutide was maintained over two years versus placebo in the studied population, addressing the durability question raised by shorter-duration trials.
Key findings
Body-weight reduction with semaglutide was maintained over two years versus placebo in the studied population, addressing the durability question raised by shorter-duration trials.
Safety summary
Adverse event profile consistent with the wider STEP programme; GI events dominant.
Limitations
- Still does not establish lifetime safety or post-discontinuation trajectory in detail.
- Sample size smaller than the pivotal STEP 1 trial.
UK relevance
Supports the durability of semaglutide 2.4 mg for weight management over two years in eligible UK patients.
- Two-year data does not equal lifetime safety data.
- Does not characterise weight trajectory after discontinuation.
Related peptide profiles
Related trials
Related conditions
Related mechanisms
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationGarvey WT et al., Two-year effects of semaglutide in adults with obesity (STEP 5). Nature Medicine 2022.
- Trial registry recordClinicalTrials.gov NCT03693430